Cerebrospinal Fluid Biomarkers in Bariatric Surgery
Primary Purpose
Obesity
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Roux-en-Y Gastric Bypass (RYGB)
Sleeve Gastrectomy (SG)
Very Low Calorie Diet (VLCD)
Sponsored by
About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Weight Loss, Low Calorie Diet
Eligibility Criteria
Inclusion Criteria:
- 18-65 years old
- BMI 35-55
Exclusion Criteria:
- No clinically significant medical conditions
- No use of tobacco
- No alcohol or drug abuse
- No recent weight change (+/-5%) within prior 6 months
- No medications that may affect body weight or blood glucose
- No diabetes medications, beta-blockers, opiates or glucocorticoids
- No pregnancy, breastfeeding, or planning to become pregnant during the study (diet group only)
- No lactose intolerance
Sites / Locations
- Columbia University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Roux-en-Y Gastric Bypass Surgery
Sleeve Gastrectomy Surgery
Very Low Calorie Diet
Arm Description
Outcomes
Primary Outcome Measures
Change in the levels of cerebrospinal fluid (CSF) proopiomelanocortin (POMC) derived peptides (fmol/ml) that occur in subjects after diet induced weight loss compared to RYGB and SG.
POMC plays a critical role in regulating energy balance and levels decrease in the hypothalamus after diet-induced weight loss; this may lead to weight regain after dieting.
Comparison of changes in the CSF proteome that occur after diet-induced weight-loss compared to RYGB and SG using unbiased proteomic analysis.
Secondary Outcome Measures
Comparison of the changes in Agouti-related protein (AgRP) concentrations (fmol/ml) in CSF and plasma that occur in subjects after diet induced weight loss compared to RYGB and SG.
AgRP is neuropeptide that stimulates food intake and increases after diet-induced weight loss.
Comparison of changes in CSF cortisol (ng/mL) that occur in subjects after diet induced weight loss compared to RYGB and SG.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04350892
Brief Title
Cerebrospinal Fluid Biomarkers in Bariatric Surgery
Official Title
Changes in Cerebrospinal Fluid Biomarkers After Bariatric Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 20, 2020 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this project is to understand why bariatric surgery is such an effective treatment for obesity with a focus on brain mechanisms. Cerebrospinal fluid (CSF) neuropeptide, hormone and protein levels will be measured as a surrogate for changes in brain activity in participants before and after bariatric surgery as compared with participants before and after diet-induced weight loss. The investigators are studying neuropeptides and hormones that are know to be involved with the regulation of appetite and body weight to determine if some of the changes that are expected to occur after diet-induced weight loss do not occur after bariatric surgery. In addition, proteomic analysis will be used to uncover new protein biomarkers that are unique to surgical weight loss. The results of these studies will help explain why bariatric surgery is so effective in achieving long-term weight loss. Understanding how the central nervous system responds to bariatric surgery could help the development of alternative nonsurgical therapies for obesity and its metabolic complications.
Detailed Description
Peripheral metabolic signals communicate levels of energy stores to the brain and elicit a host of neuronal responses that maintain energy balance; such regulatory mechanisms make it difficult to maintain diet-induced weight loss. The goal is to understand how these central regulatory mechanisms are circumvented following surgical alterations in the gut in subjects after Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (SG) compared to carefully matched diet- induced weight loss controls who achieve weight loss on a low calorie liquid diet. Surgery participants will be patients who have already chosen to have a bariatric surgery procedure with their doctor. Diet participants will be provided with the low calorie liquid diet for approximately 3 months and will be monitored weekly throughout the study.
Surgery participants will be studied at 3 time-points:
Before the intervention
After surgery at 10-15% weight loss
At 12 months after surgery
Low calorie diet participants will be studied at 2 time-points:
Before intervention
At 10-15% weight loss (approximately 12 weeks on the diet)
At each time-point subjects will have a lumbar puncture (spinal tap) for cerebrospinal fluid (CSF) sampling and blood will be collected in the fasting state and in response to a liquid meal challenge. Body weight, waist and hip circumference will be measured.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Weight Loss, Low Calorie Diet
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Cohort
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Roux-en-Y Gastric Bypass Surgery
Arm Type
Active Comparator
Arm Title
Sleeve Gastrectomy Surgery
Arm Type
Active Comparator
Arm Title
Very Low Calorie Diet
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Roux-en-Y Gastric Bypass (RYGB)
Intervention Description
This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.
If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass.
Intervention Type
Procedure
Intervention Name(s)
Sleeve Gastrectomy (SG)
Intervention Description
Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.
If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy.
Intervention Type
Behavioral
Intervention Name(s)
Very Low Calorie Diet (VLCD)
Intervention Description
Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
Primary Outcome Measure Information:
Title
Change in the levels of cerebrospinal fluid (CSF) proopiomelanocortin (POMC) derived peptides (fmol/ml) that occur in subjects after diet induced weight loss compared to RYGB and SG.
Description
POMC plays a critical role in regulating energy balance and levels decrease in the hypothalamus after diet-induced weight loss; this may lead to weight regain after dieting.
Time Frame
Up to 12 months
Title
Comparison of changes in the CSF proteome that occur after diet-induced weight-loss compared to RYGB and SG using unbiased proteomic analysis.
Time Frame
Up to 12 months
Secondary Outcome Measure Information:
Title
Comparison of the changes in Agouti-related protein (AgRP) concentrations (fmol/ml) in CSF and plasma that occur in subjects after diet induced weight loss compared to RYGB and SG.
Description
AgRP is neuropeptide that stimulates food intake and increases after diet-induced weight loss.
Time Frame
Up to 12 months
Title
Comparison of changes in CSF cortisol (ng/mL) that occur in subjects after diet induced weight loss compared to RYGB and SG.
Time Frame
Up to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18-65 years old
BMI 35-55
Exclusion Criteria:
No clinically significant medical conditions
No use of tobacco
No alcohol or drug abuse
No recent weight change (+/-5%) within prior 6 months
No medications that may affect body weight or blood glucose
No diabetes medications, beta-blockers, opiates or glucocorticoids
No pregnancy, breastfeeding, or planning to become pregnant during the study (diet group only)
No lactose intolerance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aliza Levin, BS
Phone
212-305-4006
Email
al3917@cumc.columbia.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Gerardo Febres, MD
Phone
212-342-0281
Email
gjf41@cumc.columbia.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sharon L Wardlaw, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aliza Levin, BS
Phone
212-305-4006
Email
al3917@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Gerardo Febres, MD
Phone
212-342-0281
Email
gjf41@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Sharon L Wardlaw, MD
First Name & Middle Initial & Last Name & Degree
Judy Korner, MD, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Cerebrospinal Fluid Biomarkers in Bariatric Surgery
We'll reach out to this number within 24 hrs